BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Movectro cladribine tablets regulatory update

Merck withdrew an MAA for Movectro cladribine tablets to treat relapsing-remitting multiple sclerosis (RRMS). Last month, the European Medicines Agency's CHMP issued a second recommendation against approval of the purine nucleoside analog that inhibits DNA synthesis (see BioCentury,...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >